Mitchell Capital Management Co. Has $5.53 Million Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Mitchell Capital Management Co. increased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 1.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 15,673 shares of the biotechnology company’s stock after buying an additional 190 shares during the quarter. Mitchell Capital Management Co.’s holdings in United Therapeutics were worth $5,530,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. Fisher Asset Management LLC increased its holdings in United Therapeutics by 159.1% during the 4th quarter. Fisher Asset Management LLC now owns 16,339 shares of the biotechnology company’s stock worth $5,765,000 after purchasing an additional 10,034 shares in the last quarter. Illumine Investment Management LLC bought a new position in United Therapeutics during the 4th quarter worth about $3,015,000. QRG Capital Management Inc. increased its holdings in United Therapeutics by 3.6% during the 4th quarter. QRG Capital Management Inc. now owns 16,971 shares of the biotechnology company’s stock worth $5,988,000 after purchasing an additional 591 shares in the last quarter. Proficio Capital Partners LLC bought a new position in United Therapeutics during the 4th quarter worth about $22,658,000. Finally, Oregon Public Employees Retirement Fund increased its holdings in United Therapeutics by 0.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock worth $3,214,000 after purchasing an additional 33 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $319.96 on Friday. United Therapeutics Co. has a 52-week low of $221.53 and a 52-week high of $417.82. The company has a market capitalization of $14.28 billion, a P/E ratio of 14.05, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57. The company has a 50-day simple moving average of $359.65 and a 200 day simple moving average of $360.71.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.10 by $0.09. The business had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same period last year, the business posted $4.36 EPS. As a group, equities analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Nilda Mesa sold 255 shares of United Therapeutics stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the sale, the director now directly owns 5,528 shares in the company, valued at approximately $1,966,696.56. The trade was a 4.41 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Paul A. Mahon sold 7,700 shares of United Therapeutics stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the completion of the sale, the executive vice president now owns 36,710 shares of the company’s stock, valued at approximately $13,743,122.70. The trade was a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 124,164 shares of company stock worth $45,278,893 over the last three months. Insiders own 11.90% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on UTHR. UBS Group increased their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday. Finally, HC Wainwright restated a “buy” rating and issued a $425.00 price objective on shares of United Therapeutics in a report on Thursday. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $388.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.